A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART
NCT ID: NCT00000874
Last Updated: 2013-10-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
148 participants
OBSERVATIONAL
1997-08-31
1999-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. zidovudine (ZDV) + (lamivudine) 3TC + (indinavir) IDV
2. ZDV + 3TC + saquinavir (SQV)
3. ZDV + 3TC + ritonavir (RTV)
4. stavudine (d4T) + 3TC + IDV. \[AS PER AMENDMENT 11/26/97: To determine the short-term effects of using plasma GART in the management of antiretroviral-experienced patients failing on a triple drug regimen that includes a single protease inhibitor (indinavir \[IDV\], saquinavir \[SQV\], ritonavir \[RTV\], or nelfinavir \[NFV\]) and two licensed nucleoside reverse transcriptase inhibitors (NRTIs).\] A growing body of evidence suggests that antiretroviral resistance is associated with an increased risk of disease progression and death. All commercially available antiretrovirals and many of those in development have been associated with resistance. Fortunately, techniques are available to define HIV genotypic resistance in "real time" as compared to techniques that measure phenotypic resistance that is not practical in a clinical setting. Using genotypic antiretroviral resistance testing (GART) results, along with other currently available markers, may lead to improved treatment decisions compared with using currently available markers alone.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
128 patients are randomized to GART or no GART within each of four strata defined by current antiretroviral regimen:
1. ZDV plus 3TC plus IDV
2. ZDV plus 3TC plus SQV
3. ZDV plus 3TC plus RTV
4. d4T plus 3TC plus IDV. Each of the four strata contains 22 patients with CD4+ counts of 50 - 199/mm3 and 11 patients with CD4+ counts of 200 - 500/mm3. Upon randomization, clinicians determine a treatment strategy with supplied baseline GART results (GART arm) or without them (no-GART arm). All patients remain on the triple antiretroviral regimen initiated at the randomization visit until at least the 8-week visit. At this time, changes in treatment will be allowed based on an inadequate response to therapy.
\[AS PER AMENDMENT 9/17/97: 128 patients are randomized to therapy based on GART results or therapy not based on these results. Patients are stratified into 8 groups defined by current antiretroviral regimen (ZDV/3TC/IDV vs. ZDV/3TC/SQV vs. ZDV/3TC/RTV vs. d4T/3TC/IDV) and screening CD4+ count (50-199 vs. 200-500). Management of patients assigned to the GART group is based on recommendations of study virologists after independent review of patient plasma GART results in addition to current clinical practice. Up to four different treatment regimens using only licensed drugs may be recommended, ranked but considered approximately therapeutically equivalent. The management of patients assigned to the no-GART group is based on current clinical practice and includes only licensed antiretrovirals.\] \[AS PER AMENDMENT 11/26/97: 160 patients are randomized to GART or no GART within each of 8 strata defined by current antiretroviral regimen (NRTI-1 plus NRTI-2 plus IDV vs. NRTI-1 plus NRTI-2 plus SQV vs. NRTI-1 plus NRTI-2 plus RTV vs. NRTI-1 plus NRTI-2 plus NFV) and screening CD4+ cell count.\]
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Participants who are failing a regimen of ZDV, 3TC, and IDV
No interventions assigned to this group
2
Participants who are failing a regimen of ZDV, 3TC, and SRQ
No interventions assigned to this group
3
Participants who are failing a regimen of ZDV, 3TC, and RTV
No interventions assigned to this group
4
Participants who are failing a regimen of d4T, 3TC, and IDV
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documentation of a CD4+ cell count between 50 and 500/mm3 prior to the baseline visit \[within 6 weeks prior to baseline visit AS PER AMENDMENT 9/17/97\].
* Documentation of either a plasma HIV RNA \> 50,000 copies/ml by the Roche Amplicor HIV-1 assay or \> 25,000 copies/ml by the Chiron bDNA assay, performed within 30 days prior to the baseline visit. \[AS PER AMENDMENT 9/17/97: Documentation of either a plasma HIV RNA level \>20,000 copies/ml by the Roche Amplicor HIV-1 assay or \>10,000 copies/ml by the Chiron bDNA assay, performed within 6 weeks prior to baseline visit.\]
* Documentation of a 3-fold rise in plasma HIV RNA level (using the same assay) or a previously documented plasma HIV RNA at an undetectable level while on the current antiretroviral regimen. \[AS PER AMENDMENT 9/17/97: Documentation that the screening plasma HIV RNA level is a 3-fold rise from a previous determination (using the same assay) or documentation of a previous plasma HIV RNA \<500 copies/ml while on the current antiretroviral regimen.\]
* Signed, informed consent from a parent or legal guardian for patients \< 18 years of age.
Prior Medication: Included:
* At least an 18-month cumulative history of antiretroviral therapy \[AS PER AMENDMENT 9/17/97: At least a 12-month cumulative history of antiretroviral therapy\].
Exclusion Criteria
Patients with the following conditions are excluded:
* Intercurrent illness (which in the clinician's judgment could influence the HIV RNA level) within 2 weeks prior to, or since, obtaining blood for the screening HIV RNA measurement \[within 2 weeks prior to obtaining screening HIV RNA specimen or within 2 weeks prior to baseline visit AS PER AMENDMENT 11/26/97\].
* Unwillingness or inability to change antiretroviral therapy.
* Unwillingness to wait up to 30 days after the GART baseline visit to change current triple treatment therapy regimen \[AS PER AMENDMENT 9/17/97: Unwillingness to wait until baseline plasma GART results are available to change the current triple therapy regimen\].
* Accessibility to previous genotypic or phenotypic resistance testing results.
* Co-enrollment in a clinical trial with anti-HIV drugs.
Concurrent Medication:
Excluded:
* Agents with anti-HIV activity.
* Initiation of treatment with IL-2, interferon, or adefovir dipivoxil.
* Anti-influenza or other vaccines.
Prior Medication:
Excluded:
\[AS PER AMENDMENT 11/26/97:
* Use of immunomodulators within 2 weeks prior to obtaining the screening plasma HIV RNA specimen or within 2 weeks prior to the baseline visit.
* Use of any anti-HIV agents, other than drugs in the qualifying triple antiretroviral regimen, within the past 16 weeks.\]
Patients must currently be on one of the following triple antiretroviral regimens for at least 16 weeks:
* ZDV + 3TC + IDV
* ZDV + 3TC + SQV
* ZDV + 3TC + RTV
* d4T + 3TC + IDV. \[AS PER AMENDMENT 11/26/97: Patients must currently be on a triple antiretroviral regimen that includes a single protease inhibitor (IDV, SQV, RTV, or NFV) and two licensed NRTIs for at least 16 weeks.\]
Concurent Treatment: Excluded:
* Vaccination within 2 weeks prior to, or since, obtaining blood for the screening HIV RNA measurement \[within 2 weeks prior to obtaining screening plasma HIV RNA specimen or within 2 weeks prior to the baseline visit AS PER AMENDMENT 11/26/97\].
13 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Baxter J
Role: STUDY_CHAIR
Mayers D
Role: STUDY_CHAIR
Merigan T
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Community Consortium / UCSF
San Francisco, California, United States
Community Consortium of San Francisco
San Francisco, California, United States
Alpine Family Medicine / Janowski
Denver, Colorado, United States
Denver CPCRA / Denver Public Hlth
Denver, Colorado, United States
S Denver Infectious Diseases Specialists
Denver, Colorado, United States
VA Med Ctr
Denver, Colorado, United States
Montgomery County Health Dept
Washington D.C., District of Columbia, United States
Veterans Administration Med Ctr / Regional AIDS Program
Washington D.C., District of Columbia, United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
AIDS Research Alliance - Chicago
Chicago, Illinois, United States
Louisiana Comm AIDS Rsch Prog / Tulane Univ Med
New Orleans, Louisiana, United States
Wayne State Univ / WSU / DMC HIV / AIDS Program
Detroit, Michigan, United States
Henry Ford Hosp
Detroit, Michigan, United States
Mercer Area Early Intervention Services
Camden, New Jersey, United States
Southern New Jersey AIDS Cln Trials / Dept of Med
Camden, New Jersey, United States
North Jersey Community Research Initiative
Newark, New Jersey, United States
Partners in Research / New Mexico
Albuquerque, New Mexico, United States
Partners Research
Albuquerque, New Mexico, United States
T A Ferrill Regional HIV Clinic
Albuquerque, New Mexico, United States
Harlem AIDS Treatment Group / Harlem Hosp Ctr
New York, New York, United States
The Research and Education Group
Portland, Oregon, United States
Philadelphia FIGHT
Philadelphia, Pennsylvania, United States
Saint Joseph's Hosp
Philadelphia, Pennsylvania, United States
Richmond AIDS Consortium
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Winters MA, Baxter JD, Mayers DL, Wentworth DN, Hoover ML, Neaton JD, Merigan TC. Frequency of antiretroviral drug resistance mutations in HIV-1 strains from patients failing triple drug regimens. The Terry Beirn Community Programs for Clinical Research on AIDS. Antivir Ther. 2000 Mar;5(1):57-63.
Mayers D. A Pilot Study of the Short-Term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (GART) Compared With Antiretroviral Management Without Plasma GART. (abstract no.124)
Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC. A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy. Conf Retroviruses Opportunistic Infect. 1999 Jan 31-Feb 4;6th:206 (abstract no LB8)
Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000 Jun 16;14(9):F83-93. doi: 10.1097/00002030-200006160-00001.
Baxter JD, Merigan TC, Wentworth DN, Neaton JD, Hoover ML, Hoetelmans RM, Piscitelli SC, Verbiest WH, Mayers DL; CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS. 2002 May 24;16(8):1131-8. doi: 10.1097/00002030-200205240-00006.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11598
Identifier Type: REGISTRY
Identifier Source: secondary_id
CPCRA 046
Identifier Type: -
Identifier Source: org_study_id